Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients

Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients

The coronavirus disease 2019 (COVID-19) may cause cytokine storm and respiratory illness such as pneumonia and progressive respiratory failure. Tocilizumab (TCZ), a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, was approved as an alternative treatment for severe COVID-19 patien...

Full description

Saved in:
Bibliographic Details
Main Authors: Yong Wang, Yongfeng Chen, Xiangdong Zhou
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Canadian Journal of Infectious Diseases and Medical Microbiology
Online Access:http://dx.doi.org/10.1155/2022/6375870
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items